...
首页> 外文期刊>Molecular pharmacology. >An inner pore residue (Asn406) in the Nav1.5 channel controls slow inactivation and enhances mibefradil block to T-type Ca2+ channel levels.
【24h】

An inner pore residue (Asn406) in the Nav1.5 channel controls slow inactivation and enhances mibefradil block to T-type Ca2+ channel levels.

机译:Nav1.5通道中的内部孔残渣(Asn406)控制慢速灭活并增强咪贝地尔传导阻滞至T型Ca2 +通道水平。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Mibefradil is a tetralol derivative once marketed to treat hyper-tension. Its primary target is the T-type Ca(2+) channel (IC(50), approximately 0.1-0.2 microM), but it also blocks Na(+),K(+),Cl(-), and other Ca(2+) channels at higher concentrations. We have recently reported state-dependent mibefradil block of Na(+) channels in which apparent affinity was enhanced when channels were recruited to slow-inactivated conformations. The structural determinants controlling mibefradil block have not been identified, although evidence suggests involvement of regions near or within the inner pore. We tested whether mibefradil interacts with the local anesthetic (LA) binding site, which includes residues in the S6 segments of domains (D) I, III, and IV. Mutagenesis of DIII S6 and DIVS6 did not reveal critical binding determinants. Substitution of Asn406 in DI S6 of cardiac Na(v)1.5, however, altered affinity in a manner dependent on the identity of the substituting residue. Replacing Asn406 with a phenylalanine or a cysteine increased affinity by 4- and 7-fold, respectively, thus conferring T-type Ca(2+) channel-like mibefradil sensitivity to the Na(+) channel. A series of other substitutions that varied in size, charge, and hydrophobicity had minimal effects on mibefradil block, but all mutations dramatically altered the magnitude and voltage-dependence of slow inactivation, consistent with data in other isoforms. Channels did not slow-inactivate, however, at the voltages used to assay mibefradil block, supporting the idea that Asn406 lies within or near the mibefradil binding site.
机译:Mibefradil是一种曾经出售用于治疗高血压的四氢萘酚衍生物。它的主要目标是T型Ca(2+)通道(IC(50),大约0.1-0.2 microM),但它也可以阻止Na(+),K(+),Cl(-)和其他Ca( 2+)浓度较高的通道。我们最近报道了Na(+)通道的状态依赖性mibefradil阻滞,其中当通道被募集为缓慢灭活的构象时,表观亲和力得到了增强。尽管证据表明内孔附近或内部区域参与,但尚未确定控制咪贝地尔传导阻滞的结构决定因素。我们测试了米贝拉地尔是否与局部麻醉剂(LA)结合位点相互作用,该结合位点包括域(D)I,III和IV的S6片段中的残基。 DIII S6和DIVS6的诱变没有揭示关键的结合决定因素。然而,Asn406在心脏Na(v)1.5的DI S6中的取代以依赖于取代残基身份的方式改变了亲和力。分别用苯丙氨酸或半胱氨酸取代Asn406增加4和7倍的亲和力,从而赋予Na(+)通道的T型Ca(2+)通道样mibefradil敏感性。一系列其他大小,电荷和疏水性不同的取代对咪贝地尔阻滞的影响最小,但所有突变均显着改变了慢灭活的幅度和电压依赖性,这与其他同工型的数据一致。然而,通道并没有在用于测定米贝地尔传导阻滞的电压下缓慢失活,这支持了Asn406位于米贝地尔结合位点之内或附近的想法。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号